| [1] |
Habermann EB, Abbott A, Parsons HM, et al. Are mastectomy rates really increasing in the United States? [J]. J Clin Oncol, 2010, 28(21): 3437-3441.
|
| [2] |
Del Turco MR, Ponti A, Bick U, et al. Quality indicators in breast cancer care [J]. Eur J Cancer, 2010, 46(13): 2344-2356.
|
| [3] |
Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China [J]. Lancet Oncol, 2014, 15(7): e279-e289.
|
| [4] |
Bao X, Sun K, Tian X, et al. Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10-year (2006－2015) retrospective hospitalization summary report-based study [J]. Thorac Cancer, 2018, 9(6): 707-717.
|
| [5] |
Kong Y, Yang L, Tang H, et al. A nation-wide multicenter retrospective study of the epidemiological, pathological and clinical characteristics of breast cancer in situ in Chinese women in 1999 － 2008 [J]. PLoS One, 2013, 8(11): e8 1055.
|
| [6] |
Ordu C, Mcguire K, Alco G, et al. The prognostic impact of molecular subtypes and very young age on breast conserving surgery in early stage breast cancer [J]. Cureus, 2016, 8(6): e633.
|
| [7] |
Lertsithichai P, Sakulchairungreung B, Chirappapha P, et al. Effect of young age, positive margins, and triple negative status on disease recurrence after breast conserving therapy [J]. Gland Surg, 2016, 5(1): 15-23
|
| [8] |
Kim SW, Chun M, Han S, et al. Young age is associated with increased locoregional recurrence in node-positive breast cancer with luminal subtypes [J]. Cancer Res Treat, 2017, 49(2): 484-493.
|
| [9] |
Kim IK, Park S, Hwang H, et al. Clinical significance of age at the time of diagnosis among young breast cancer patients [J]. J Breast Cancer, 2011, 14(4): 314-321.
|
| [10] |
Goksu SS, Tastekin D, Arslan D, et al. Clinicopathologic features and molecular subtypes of breast cancer in young women (age ≤35) [J]. Asian Pac J Cancer Prev, 2014, 15(16): 6665-6668.
|
| [11] |
Wong FY, Tham WY, Nei WL, et al. Age exerts a continuous effect in the outcomes of Asian breast cancer patients treated with breast-conserving therapy [J]. Cancer Commun (Lond), 2018, 38(1): 39.
|
| [12] |
Foo CS, Su D, Chong CK, et al. Breast cancer in young Asian women: study on survival [J]. ANZ J Surg, 2005, 75(7): 566-572.
|
| [13] |
Erdem E, Alagol H. Results of breast conserving surgery in clinical stage Ⅰ－Ⅱ breast carcinoma [J]. Indian J Surg, 2009, 71(1): 29-34.
|
| [14] |
Shafik YS, Rafik H, Helmy M. Factors contributing to local recurrence after conservative breast surgery for early-stage breast cancer [J]. Egypt J Surg, 2018, 37(4): 429-439.
|
| [15] |
Wang L, Li J, Wang T, et al. Impact of clinical and pathological factors on local recurrence after breast-conserving treatment: CT-based localization for a tumor bed boost yielded better local control when compared with a surgical scar [J]. J Cancer, 2019, 10(3): 708-715.
|
| [16] |
Livi L, Paiar F, Saieva C, et al. Survival and breast relapse in 3834 patients with T1－T2 breast cancer after conserving surgery and adjuvant treatment [J]. Radiother Oncol, 2007, 82(3): 287-293.
|
| [17] |
Mirza NQ, Vlastos G, Meric F, et al. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy [J]. Ann Surg Oncol, 2002, 9(3): 256-265.
|
| [18] |
Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage Ⅰ－Ⅱ breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial [J]. Lancet Oncol, 2012, 13(4): 412-419.
|
| [19] |
Libson S, Koshenkov V, Rodgers S, et al. Breast conservation after neoadjuvant therapy for tumors ≥5 cm: A prospective cohort study [J]. Int J Surg Open, 2015, 1: 10-13.
|
| [20] |
Mazor AM, Mateo AM, Demora L, et al. Breast conservation versus mastectomy in patients with T3 breast cancers (> 5 cm): an analysis of 37，268 patients from the National Cancer Database [J]. Breast Cancer Res Treat, 2019, 173(2): 301-311.
|
| [21] |
Braunstein LZ, Taghian AG, Niemierko A, et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy [J]. Breast Cancer Res Treat, 2016, 161(1): 173-179.
|
| [22] |
Elsayed M, Alhussini M, Basha A, et al. Analysis of loco-regional and distant recurrences in breast cancer after conservative surgery [J]. World J Surg Oncol, 2016, 14:144.
|
| [23] |
Dings PJ, Elferink MA, Strobbe LJ, et al. The prognostic value of lymph node ratio in node-positive breast cancer: A dutch nationwide population-based study [J]. Ann Surg Oncol, 2013, 20(8): 2607-2614.
|
| [24] |
Su S, Wang C, Wang X, et al. Prognostic value of combining lymph node ratio and number of positive lymph nodes in breast cancer: A population-based study [J]. Breast J, 2019, 25(5): 1020-1022.
|
| [25] |
Mittendorf EA, Buchholz TA, Tucker SL, et al. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy [J]. Ann Surg, 2013, 257(2): 173-179.
|
| [26] |
Yamazaki N, Wada N, Yamauchi C, et al. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy [J]. Eur J Surg Oncol, 2015, 41(5): 617-624.
|
| [27] |
Mohammed RA, Martin SG, Mahmmod AM, et al. Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up [J]. J Pathol, 2011, 223(3): 358-365.
|
| [28] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版) [J]. 中国癌症杂志，2019, 29(8): 609-679.
|
| [29] |
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J]. Ann Oncol, 2013, 24(9): 2206-2223.
|
| [30] |
Lowery AJ, Kell MR, Glynn RW, et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype [J]. Breast Cancer Res Treat, 2012, 133(3): 831-841.
|
| [31] |
Gangi A, Chung A, Mirocha J, et al. Breast-conserving therapy for triple-negative breast cancer [J]. JAMA Surg, 2014, 149(3): 252-258.
|
| [32] |
Mcguire A, Lowery AJ, Kell MR, et al. Locoregional recurrence following breast cancer surgery in the trastuzumab era: A systematic review by subtype [J]. Ann Surg Oncol, 2017, 24(11): 3124-3132.
|
| [33] |
Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer [J]. J Clin Oncol, 2009, 27(15): 2466-2473.
|
| [34] |
Pilewskie M, Morrow M. Margins in breast cancer: How much is enough? [J]. Cancer, 2018, 124(7): 1335-1341.
|
| [35] |
Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer [J]. N Engl J Med, 1985, 312(11): 665-673.
|
| [36] |
Veronesi U, Volterrani F, Luini A, et al. Quadrantectomy versus lumpectomy for small size breast cancer [J]. Eur J Cancer, 1990, 26(6): 671-673.
|
| [37] |
Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy [J]. Eur J Cancer, 2010, 46(18): 3219-3232.
|
| [38] |
Azu M, Abrahamse P, Katz SJ, et al. What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates [J]. Ann Surg Oncol, 2010, 17(2): 558-563.
|
| [39] |
Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer [J]. Ann Surg Oncol, 2014, 21(3): 704-716.
|
| [40] |
Houssami N, Macaskill P, Marinovich ML, et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis [J]. Ann Surg Oncol, 2014, 21(3): 717-730.
|
| [41] |
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials [J]. Lancet, 2005, 366(9503): 2087-2106.
|
| [42] |
Darby S, Mcgale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10，801 women in 17 randomised trials [J]. Lancet, 2011, 378(9 804): 1707-1716.
|
| [43] |
Speers C, Pierce LJ. Postoperative radiotherapy after breast-conserving surgery for early-stage breast cancer: A review [J]. JAMA Oncol, 2016, 2(8): 1075-1082.
|
| [44] |
Polgár C, Fodor J, Major T, et al. Breast-conserving therapy with partial or whole breast irradiation: Ten-year results of the Budapest randomized trial [J]. Radiother Oncol, 2013, 108(2): 197-202.
|
| [45] |
Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial [J]. Lancet, 2017, 390(10 099): 1048-1060.
|
| [46] |
Polgár C, Van Limbergen E, Pötter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009) [J]. Radiother Oncol, 2010, 94(3): 264-273.
|
| [47] |
Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial [J]. Lancet, 2014, 383(9917): 603-613.
|
| [48] |
Zhang L, Zhou Z, Mei X, et al. Intraoperative radiotherapy versus whole-breast external beam radiotherapy in early-stage breast cancer: A systematic review and meta-analysis [J]. Medicine (Baltimore), 2015, 94(27): e1143.
|
| [49] |
Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 4.2017, NCCN Clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2018, 16(3): 310-320.
|
| [50] |
Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2015, 26 Suppl 5:v8-v30.
|
| [51] |
Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer [J]. N Engl J Med, 2018, 379(2): 122-137.
|
| [52] |
Lippman ME. Endocrine adjuvant therapy for localized breast cancer [J]. N Engl J Med, 2018, 379(2): 193-194.
|
| [53] |
Wenners A, Berlin L, Alkatout I, et al. Clinical implications of first and multiple locoregional breast cancer recurrences [J]. Arch Gynecol Obstet, 2014, 292(1): 165-173.
|
| [54] |
Mamounas EP, Tang G, Liu Q. The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience [J]. J Surg Oncol, 2014, 110(1): 45-50.
|
| [55] |
Bhatti AB, Jamshed A, Shah M, et al. Breast conservative therapy in Pakistani women: Prognostic factors for locoregional recurrence and overall survival [J]. J Cancer Res Ther, 2015, 11(2):300-304.
|
| [56] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2018.V1[M]. 北京：人民卫生出版社，2018.
|
| [57] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J]. Lancet, 2013, 381(9869): 805-816.
|
| [58] |
Tovar JR, Zandonade E, Amorim MH. Factors associated with the incidence of local recurrences of breast cancer in women who underwent conservative surgery [J]. Int J Breast Cancer, 2014, 2014: 639 534.
|
| [59] |
Bellon JR, Guo H, Barry WT, et al. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) [J]. Breast Cancer Res Treat, 2019, 176(2): 303-310.
|
| [60] |
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 [J]. Ann Oncol, 2017, 28(8): 1 700-1 712.
|
| [61] |
Von Minckwitz G, Procter M, De Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [J]. N Engl J Med, 2017, 377(2): 122-131.
|